Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Immunocytochemistry [1]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-99463 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Cyclin F Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- Antibody detects endogenous levels of total Cyclin F.
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 1 mg/mL
- Storage
- -20°C
Submitted references A Novel Signature of CCNF-Associated E3 Ligases Collaborate and Counter Each Other in Breast Cancer.
Chang SC, Hung CS, Zhang BX, Hsieh TH, Hsu W, Ding JL
Cancers 2021 Jun 8;13(12)
Cancers 2021 Jun 8;13(12)
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of Cyclin F in HeLa cells. Samples were fixed with paraformaldehyde, permeabilized with 0.1% Triton X-100, blocked with 10% serum (45 min at 25°C) incubated with Cyclin F polyclonal antibody (Product # PA5-99463) using a dilution of 1:200 (1 hr, 37°C), and followed by goat anti-rabbit IgG Alexa Fluor 594 at a dilution of 1:600.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of Cyclin F in human Breast cancer tissue sections. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. Samples were incubated with Cyclin F polyclonal antibody (Product # PA5-99463) using a dilution of 1:200 (1.5 hours at 22°C) followed by HRP conjugated goat anti-rabbit secondary antibody.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 Transcriptional profiles of the main components of SCF E3 from the TCGA database of human primary BRCA tissues. To clarify the potential of the identified SCF E3 ligase, both TCGA database results ( A - C ) and IHC results ( D ) were analyzed. ( A ) As a key E1 component, UBA1 was elevated in BRCA tissues throughout all disease stages. ( B ) UBE2C, UBE2T, and UBE2O were identified as the main E2 components, showing significant overexpression in breast carcinoma tissues, particularly in advanced stages. ( C ) Investigation of FBXL8 profiling was recently studied in BRCA tissues []. Here, we further reported that CCNF, FBXO43, and FBXO15 were identified as the main E3 F-box components, which show significant overexpression in carcinoma tissues. Y-axis: normalized count, X-axis: pathological cancer stages. The number of samples in each stage is shown in parentheses: stage I/0 ( n = 182), stage II ( n = 624), stage III ( n = 251), and stage IV ( n = 20). N: normal ( n = 113). *, p < 0.05; **, p < 0.01. ( D ) shows H&E and immunofluorescence staining. Protein expression levels of CCNF, FBXO43, and FBXO15 were examined in both breast carcinoma ( n = 30) and paired normal breast tissues ( n = 30). The corresponding quantitative results of CCNF, FBXO43, and FBXO15 in IHC are shown in ( E - G ), respectively. Consistent with our observation of the mRNA levels, the FBXL8 [], FBXO43, and FBXO15 proteins are significantly upregulated in breast carcinoma tissues compared with nor
